SK Life Science Inc., a subsidiary of South Kore-based SK Biopharmaceuticals Co. Ltd, announced on Thursday that it has received US Food and Drug administration (FDA) approval for the investigational new drug (IND) application to study SKL27969 as a potential treatment for advanced solid tumours.
The company is to carry out a Phase 1/2 open-label, non-randomised, multicentre, dose escalation and expansion study aimed at assessing the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of SKL27969 in adult patients with solid tumours.
Marc Kamin, MD, chief medical officer at SK life science, said, 'We look forward to learning more about the potential of SKL27969 as a treatment option for a range of advanced solid tumours. We are excited to expand our R&D efforts into discovering potential new therapies for cancer.'
Perrigo's Omeprazole Magnesium Delayed-Release Mini Capsules receives US FDA final approval
Nanoscope Therapeutics names new advisors to company's Board and Management
Alcon to expand ophthalmic eye drop portfolio with acquisition of EYSUVIS
Third shot of Pfizer-BioNTech vaccine '80% effective' against Omicron in under-5s
STADA Arzneimittel's Kinpeygo receives positive EU regulator opinion for IgAN kidney disease
Astellas receives unfavourable decision in LEXISCAN(R) 0.4mg/mL US patent trial